BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic.
Also Read: FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax’s Shot.
These companies, whose stocks plummeted by about 80% since their 2021 pandemic peaks, are now focusing on cancer treatments to revive their fortunes.
The personalized approach, though promising, faces skepticism due to the high cost and difficulty of scaling production.
Miranda Payne, a ...
